p53-oriented cancer therapies: current progress (Q33545318)

27 July 2017

1 reference

title

p53-oriented cancer therapies: current progress (English)

1 reference

27 July 2017

W M Gallagher

1

1 reference

27 July 2017

R Brown

series ordinal

2

1 reference

27 July 2017

publication date

1 February 1999

1 reference

27 July 2017

1 reference

27 July 2017

volume

10

1 reference

27 July 2017

issue

2

1 reference

27 July 2017

page(s)

139-150

1 reference

27 July 2017

cites work

p53: puzzle and paradigm

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53; from inductive signal to cellular effect

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Heat shock induces transient p53-dependent cell cycle arrest at G1/S

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 in signaling checkpoint arrest or apoptosis

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Radiation-induced cell cycle arrest compromised by p21 deficiency

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

A p53-dependent mouse spindle checkpoint

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Thymocyte apoptosis induced by p53-dependent and independent pathways.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 is required for radiation-induced apoptosis in mouse thymocytes

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Life, death, and the pursuit of apoptosis.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

The dominating effect of mutant p53

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Two cellular proteins that bind to wild-type but not mutant p53

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

MDM2 and p53: a question of balance

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

MDM2-arbiter of p53's destruction

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

DNA damage activates p53 through a phosphorylation-acetylation cascade

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

DNA damage induces phosphorylation of the amino terminus of p53

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Implications of the p53 tumor-suppressor gene in clinical oncology.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Clinical implications of the p53 gene

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Cancer therapy and p53.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Cell-cycle arrest versus cell death in cancer therapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

The p53 proto-oncogene can act as a suppressor of transformation

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Gene therapy for cancer: what have we done and where are we going?

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Intercellular delivery of functional p53 by the herpesvirus protein VP22.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Hepatocellular carcinoma and p53 gene therapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Cationic liposomes for direct gene transfer in therapy of cancer and other diseases.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Structure-based rescue of common tumor-derived p53 mutants

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Therapeutic targeting of the p53 tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

A temperature-sensitive mutant of human p53.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Geldanamycin Prevents Nuclear Translocation of Mutant p53

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Oligonucleotide-mediated modulation of mammalian gene expression.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 activity and chemotherapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53: a target for new anticancer drugs or a target for old drugs?

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 as a target for anti-cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Mutant Oncopeptide Immunization Induces CTL Specifically Lysing Tumor Cells Endogenously Expressing the Corresponding Intact Mutant p53

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Idiotypic immunization induces immunity to mutated p53 and tumor rejection

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Converting cancer genes into killer genes

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53/E1b58kDa Complex Regulates Adenovirus Replication

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Killing tumor cells with viruses--a question of specificity

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

1 reference

https://api.crossref.org/works/10.1023/A:1008368500557

7 January 2021

Identifiers

DOI

10.1023/A:1008368500557

1 reference

27 July 2017

1 reference